Sulfur Containing Patents (Class 536/54)
-
Patent number: 5644042Abstract: A process for the preparation of aldobionamides directly from an aldobionic acid starting material, in which an aldobionic acid is reacted by removing water by azeotropic distillation to obtain an aldobionolactone. The aldobionolactone can then be reacted with amines without further purification or isolation steps to obtain the aldobionamide.Type: GrantFiled: December 21, 1995Date of Patent: July 1, 1997Assignee: Solvay Pharma Deutschland GmbHInventors: Klaus Guenther Gerling, Claudia Schreer, Petra Schwarz, Kornelia Wendler
-
Patent number: 5639734Abstract: The present invention provides a composition of matter comprising a biosynthetic anti-inflammatory oligosaccharide, comprising the structure of: sugar - sugar - X - R; wherein said sugar is selected from the group consisting of N-acetylneuraminic acid, galactose, N-acetylglucosamine, N-acetylgalactosamine, fucose and mannose; wherein X is a bridging atom selected from the group consisting of oxygen, sulfur, nitrogen and carbon; and wherein R is an aglycone selected from the group consisting of naphthol, naphthalenemethane, indenol, a heterocyclic derivative of indenol, a heterocyclic derivative of naphthol and a heterocyclic derivative of naphthalenemethanol. Also provided is a method of treating an inflammatory disease in an individual comprising the step of administering to said individual a therapeutically effective dose of the novel composition of the present invention.Type: GrantFiled: December 20, 1994Date of Patent: June 17, 1997Inventors: Jeffrey D. Esko, Arun K. Sarkar
-
Patent number: 5624839Abstract: Hepatocytes spheroids can be formed by culturing hepatocytes in a culture vessel using a lipid-bound glycosaminoglycan as a culture substrate. Floating spheroids of hepatocytes can be obtained efficiently, which are capable of maintaining liver-specific functions and of keeping the spheroid form stably for a prolonged period of time.Type: GrantFiled: May 30, 1995Date of Patent: April 29, 1997Assignee: Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation)Inventors: Toshikazu Yada, Norio Koide, Koji Kimata
-
Patent number: 5589588Abstract: A sulfated acid amide having heparin-like properties of the formula:(R.sub.1)--NH--R--NH--(R.sub.1)whereR.sub.1 is a di-, tri- or tetra-saccharide acid selected from cellobiose, cellotriose, cellotetrose, maltose, maltotriose and maltotetrose or mixtures thereof, andR is an alkylene of from 3 to 12 carbons, and is optionally substituted with one or more hydroxyls.Type: GrantFiled: March 30, 1993Date of Patent: December 31, 1996Assignee: Reliable Biopharmaceutical CorporationInventor: Joseph A. Toce
-
Patent number: 5580858Abstract: Disclosed are novel Lewis.sup.x and Lewis.sup.a analogues, pharmaceutical compositions containing such analogues, methods for their preparation and methods for their use.Type: GrantFiled: November 4, 1994Date of Patent: December 3, 1996Assignee: Alberta Research CouncilInventors: Robert M. Ippolito, Wasimul Haque, Cong Jiang, H. Rizk Hanna, Andre P. Venot, Pandurang V. Nikrad, Mohammed A. Kashem, Richard H. Smith
-
Patent number: 5580862Abstract: Sulfated oligosaccharides which bind to selectin receptors and act as agonists are formulated into pharmaceutical formulations and administered by injection to treat inflammation. Compounds such as chlorates which act as metabolic inhibitors of carbohydrate sulfation and inhibit the sulfation of naturally occurring ligands for selectin receptors are administered locally by injection to alleviate and/or prevent inflammation. Sulfatase is administered which removes a sulfate moiety from a natural sulfated ligand. The sulfated oligosaccharides can be administered in combination with the chlorates and sulfatases in order to obtain a combined effect which is useful in preventing and/or alleviating inflammation.Type: GrantFiled: April 14, 1995Date of Patent: December 3, 1996Assignee: The Regents of the University of CaliforniaInventors: Steven D. Rosen, Yasuyuki Imai
-
Patent number: 5576304Abstract: A pharmaceutical composition comprising dermatan sulphate, together with a low molecular weight heparin, free or fixed combination, is useful as a antithrombolytic agent with a low risk of bleeding complications.Type: GrantFiled: July 9, 1991Date of Patent: November 19, 1996Assignee: Thrombosis Research InstituteInventors: Vijay V. Kakkar, Michael F. Scully
-
Patent number: 5563250Abstract: The present invention provides cleavable conjugates whose linkers contain a labile bond that is cleavable under a variety of mild conditions, including weakly acidic. Since the agent may be bonded directly to the linker, cleavage can result in release of native agent. The invention also provides methods for producing cleavable conjugates. Preferred agents include drugs, toxins, biological response modifiers, radiodiagnostic compounds, radiotherapeutic compounds, and derivatives thereof. The targeting molecule employed in the invention may be an intact molecule, a fragment thereof, or a functional equivalent thereof. In a particularly preferred embodiment, the targeting molecule is a monoclonal antibody directed towards a tumor-associated antigen in man. The invention further provides methods for delivering to the cytoplasm of a target cell an agent free of its targeting molecule carrier.Type: GrantFiled: May 13, 1994Date of Patent: October 8, 1996Assignee: NeoRx CorporationInventors: Mark D. Hylarides, Ananthachari Srinivasan, Jeffrey N. Fitzner, Vivekananda M. Vrudhula
-
Patent number: 5559103Abstract: The present invention relates to bivalent sialyl Lewis X saccharide compounds that inhibit cellular binding to a selectin receptor. Pharmaceutical compositions containing a compound of Formula I, and processes for making and using the same are disclosed. A contemplated bivalent sialyl Lewis X saccharide compound has a structure that corresponds to Formula I, below, ##STR1## wherein R is a directly linked divalent monosaccharide unit; Y is selected from the group consisting of C(O), SO.sub.2, HNC(O), OC(O) and SC(O);R.sup.2 is selected from the group consisting of a C.sub.1 -C.sub.6 hydrocarbyl, an aryl, a substituted aryl and a phenyl C.sub.1 -C.sub.3 alkylene group, wherein an aryl group has one six-membered aromatic ring or two fused six-membered aromatic rings, which ring or rings are hydrocarbyl, monoazahydrocarbyl, or diazahydrocarbyl rings, and a substituted aryl group is a before-mentioned aryl group having a substituent selected from the group consisting of halo, trifluoromethyl, nitro, C.sub.1 -C.Type: GrantFiled: July 20, 1994Date of Patent: September 24, 1996Assignee: Cytel CorporationInventors: Federico C. A. Gaeta, Shawn A. DeFrees
-
Patent number: 5550116Abstract: The invention relates to N,O-sulphated heparosans consisting of chains or of a mixture of chains of molecular mass between 1500 and 15,000 Da, characterized by a repeated disaccharide structure of formula I: ##STR1## in which: E represents an acetyl group in 0 to 80% of the disaccharide units of the said N,O-sulphated heparosan, and a sulphate group and possibly a hydrogen atom in the remaining disaccharide units,G represents a hydrogen atom and a sulphate group, and the pharmaceutically acceptable salts of thesaid N,O-sulphated heparosans. The heparosans are useful as anticoagulants.Type: GrantFiled: February 15, 1995Date of Patent: August 27, 1996Assignee: SanofiInventors: Jean Claude Lormeau, Bruno Chevallier, Marc L. V. Salom e, Guy E. M. Tenaille d'Estais
-
Patent number: 5547944Abstract: A natural dermatan sulphate with antithrombinic activity in excess of 220 U/mg which comprises an oligosaccharide sequence with a high degree of sulfation, having formula (III) ##STR1## in which: n=integers 1 or 2; R.sub.4 =SO.sub.3, or H; R.sub.6 =H, or SO.sub.3 ; G=glucuronic acid: I--non-sulfated uronic acid, preferably glucuronic acid, is extracted from organs, and subsequently purified in mild operating conditions, at pH 5-7, isolation and fractionation being carried out with macroreticular ion exchange resins, having a particle size of less than 10 .mu..Type: GrantFiled: February 23, 1994Date of Patent: August 20, 1996Assignee: Opocrin S.p.A.Inventors: Giuseppe Mascellani, Pietro Bianchini
-
Patent number: 5541166Abstract: A method of anti-metastatic and/or anti-inflammatory treatment of an animal or human patient comprises administration to the patient of an effective amount of at least one sulphated polysaccharide which blocks or inhibits endoglycosidase, particularly heparanase, activity. Suitable sulphated polysaccharides include heparin and modified heparin, fucoidan, pentosan sulphate, dextran sulphate and carrageenan lambda.Type: GrantFiled: March 16, 1992Date of Patent: July 30, 1996Assignee: The Australian National UniversityInventors: Christopher R. Parish, John M. Snowden
-
Patent number: 5521293Abstract: The present invention relates to a process for producing amido heteroatom containing alkyl aldonamides comprising reacting an amino heteroatom containing alkyl aldonamide and an acid anhydride in water or solvent; heating the mixture and recovering. A second embodiment of the invention relates to a process for making alkoxylated derivatives of heteroatom containing alkyl aldonamide compounds.Type: GrantFiled: May 8, 1995Date of Patent: May 28, 1996Assignee: Lever Brothers Company, Division of Conopco, Inc.Inventors: Robert Vermeer, Van Au, Bijan Harichian
-
Patent number: 5519010Abstract: The present invention provides a sulfated polysaccharide (D-HG), a pharmaceutically acceptable salt thereof, a process for preparing the same and a medicament containing the same as the effective component for DIC (disseminated intravascular coagulation) and thrombosis, the sulfated polysaccharide (D-HG) being prepared by depolymerization of FGAG (a sulfated polysaccharide extracted from a body wall of a sea cucumber with such activities as those of heparin) or a salt thereof and having the following physicochemical properties:[1] Molecular weight:3,000 to 42,000 (as measured by high performance GPC)[2] Characteristic:white, amorphous, highly hygroscopic powder[3] Solubility:soluble in water but insoluble in ethanol, acetone and like organic solvents[4] Specific rotation:[.alpha.].sub.D.sup.20 =-55 to -73.degree.Type: GrantFiled: May 12, 1994Date of Patent: May 21, 1996Assignees: Taiho Pharmaceutical Co., Ltd., Kotai Kasei Co., Ltd.Inventors: Hui-Zeng Fan, Song Yu, Etsuji Yamanaka, Kazuhiro Numata, Toshinori Oka, Norihiko Suzuki, Yoshiyuki Muranaka
-
Patent number: 5508387Abstract: Glyco-amino acids or glycopeptides that have three-dimensionally stable configuration for the presentation of functional groups, fucose, or an analogue or derivative thereof, covalently linked to an amino acid or peptide with a free carboxylic acid group, that facilitate binding between those groups and receptors on selectins, represented by the general structural formula I.Type: GrantFiled: August 4, 1993Date of Patent: April 16, 1996Assignee: Glycomed IncorporatedInventors: Peng C. Tang, Daniel E. Levy, Kevin R. Holme, Saeed A. Abbas
-
Patent number: 5489578Abstract: Sulfated oligosaccharides which bind to L-selectin receptors and act as agonists are formulated into pharmaceutical formulations and administered by injection to treat inflammation. Compounds which act as metabolic inhibitors of carbohydrate sulfation and inhibit the sulfation of naturally occurring ligands for L-selectin receptors are administered locally by injection to alleviate and/or prevent inflammation. The sulfated oligosaccharides can be administered in combination with the chlorates and sulfatases in order to obtain a combined effect which is useful in preventing and/or alleviating inflammation. A preferred group of ligands are obtained by the hydrolysis of GlyCAM-1 by separation procedures including high pH anion exchange chromatography. The invention describes compounds that have the recognition determinants for L-selectin on GlyCAM-1 as Galactose-6-sulfate and/or N-acetylglucosamine-6-sulfate, in concert with sialic acid and fucose.Type: GrantFiled: May 2, 1996Date of Patent: February 6, 1996Assignee: The Regents of the University of CaliforniaInventors: Steven D. Rosen, Stefan Hemmerich
-
Patent number: 5489675Abstract: Novel NeuAc-Gal dissacharide sialidase substrates and inhibitors which are locked into rigid conformation by the attachment of an alkyl group at the C-6 arm of the galactose core are provided. Also provided is a method for the inhibition of sialidase activity.Type: GrantFiled: November 3, 1993Date of Patent: February 6, 1996Assignee: E. I. Du Pont de Nemours and CompanyInventor: Subramaniam Sabesan
-
Patent number: 5474987Abstract: The present invention relates to methods for the prevention and/or treatment of pathological processes involving the induction of TNF-.alpha. secretion comprising a pharmaceutically acceptable carrier and a low molecular weight heparin (LMWH). In the pharmaceutical compositions of the present invention, the LMWH is present in a low effective dose and is administered at intervals of about 5-8 days. Furthermore, the LMWH is capable of inhibiting in vitro TNF-.alpha. secretion by resting T cells and/or macrophages in response to T cell-specific antigens, mitogens, macrophage activators, disrupted extracellular matrix (dECM), laminin, fibronectin, and the like.Type: GrantFiled: February 3, 1995Date of Patent: December 12, 1995Assignee: Yeda Research and Development Co. Ltd.Inventors: Irun R. Cohen, Ofer Lider, Rami Hershkoviz
-
Patent number: 5470840Abstract: Multivalent metal ion complexes of a polysulfate of xylan having glycosidically linked D-glucuronyl side chains or derivatives thereof are provided, together with therapeutic compositions thereof having anti-inflammatory activity.Type: GrantFiled: June 10, 1992Date of Patent: November 28, 1995Assignee: Arthropharm Pty LimitedInventors: David Cullis-Hill, Peter Ghosh
-
Patent number: 5464942Abstract: This invention relates to compounds prepared by linking glycosaminoglycan to phospholipid or lipid, which are expected to exert a pharmacological effect for inhibiting metastasis because of their excellent function to inhibit adhesion of cancer cells to blood vessel endothelial cells and extracellular matrix. This phospholipid- or lipid-linked glycosaminoglycan can be produced for example by: cleaving and oxidizing reducing terminal group of glycosaminoglycan, and allowing an aldehyde group or a lactone compound of the thus-formed derivative or a carboxyl group in the glycosaminoglycan chain to react with a primary amino group of a phospholipid; or linking a glycosaminoglycan derivative to a phospholipid or a lipid by allowing a primary amino group of the derivative to react with a carboxyl group of the phospholipid or lipid. This phospholipid- or lipid-linked glycosaminoglycan is useful as a metastasis inhibitor because it has no toxicity.Type: GrantFiled: March 24, 1991Date of Patent: November 7, 1995Assignee: Seikagaku Kogyo Kabushiki KaishaInventors: Katsukiyo Sakurai, Nobuo Sugiura, Koji Kimata, Sakaru Suzuki
-
Patent number: 5441932Abstract: An inhibitor of the biosynthesis of sugar chains containing sialic acid that is excellent in the suppression of inflammation or allergy, which comprises as an active ingredient a sugar compound of the formula (1): ##STR1## wherein R.sup.1 is a hydrogen atom, a substituted or unsubstituted aliphatic hydrocarbon group, a substituted or unsubstituted aromatic hydrocarbon group, a peptide residue or a glycoprotein, and R.sup.2 is a hydrogen atom, a sulfhydryl group, an acyloxy group, an acylthio group, an aryloxy group, an alkyloxy group or a glycothio residue. The inhibitor of the biosynthesis of sugar chains containing sialic acid may be used as a therapeutic agent for inflammation caused by sugar chains containing sialic acid.Type: GrantFiled: March 2, 1993Date of Patent: August 15, 1995Assignee: Japan Tobacco, Inc.Inventors: Hisashi Kodama, Hironobu Hashimoto, Yasuhiro Kajihara
-
Patent number: 5426182Abstract: Polysaccharides, including hydroxyethyl cellulose, having complex hydrophobic group substitution, provide latex compositions, such as paints, with improved rheology and stability. Improved processes for producing such polysaccharides are also provided.Type: GrantFiled: May 29, 1992Date of Patent: June 20, 1995Assignee: Union Carbide Chemical & Plastics Technology CorporationInventors: Richard D. Jenkins, David R. Bassett, Gregory D. Shay
-
Patent number: 5403922Abstract: The subject of the invention is a surface-active composition, comprising a bolaamphiphile or bolaform chemical compound, containing a linear or branched, hydrophobic carbon chain at the two ends of which are arranged two hydrophilic portions or head group groups, corresponding to the following general formula:R A E A Rin which:E represents the carbon chain, containing at least six carbon atoms, optionally interrupted by at least one aromatic, or heterocyclic, or functional groupA is a bonding functional groupR is a residue of a reducing glucide containing a linear or cyclized chain, or of a derivative of the said glucide, bonded directly or indirectly via one of its aldehyde or ketone functional groups, or derived functional group, to the functional group A.The invention also relates to their applications as components of surface-active agents and vesicular agents, and to a process for their preparation.Type: GrantFiled: June 7, 1994Date of Patent: April 4, 1995Inventors: Rachel Garelli-Calvet, Florence Brisset, Isabelle Rico, Armand Lattes, Lionel Godefroy
-
Patent number: 5403827Abstract: There is provided a process for preparing epoxy-heparide polysaccharides of formula (I): ##STR1## wherein A is a pyran ring with substituents 1 and 4 in the axial position and 5 in the equatorial position, and R and R' are hexosamines which constitute a polysaccharide chain bonded to said ring A by a glucoside, and one of R and R' is H when the ring A is in the terminal position of said polysaccharide chains, and said heparide has a COCH.sub.3 to COOH ratio of 0.5, said process comprisinga) N-desulfation of heparin to obtain the corresponding heparamine;b) acetylation of the heparamine of step (a) to obtain the corresponding heparide;c) epoxidation of the heparide of step (b) by treating the heparide with hydrogen peroxide in an alkaline reaction medium at pH 12-14; andd) cooling the solution obtained in step (c) to a temperature of between 15.degree. and 25.degree. C. and adjusting the pH to between 5.8 and 6.0.Type: GrantFiled: November 2, 1993Date of Patent: April 4, 1995Assignee: Laboratori Derivati Organici S.p.A.Inventor: Luigi De-Ambrosi
-
Patent number: 5391726Abstract: The invention concenrs giant ring compounds containing about 20 to about 160 atoms in the backbone of the ring and methods for preparing the giant ring compounds.Type: GrantFiled: April 30, 1992Date of Patent: February 21, 1995Assignee: The Dow Chemical CompanyInventor: Fredric M. Menger
-
Patent number: 5380829Abstract: Disclosed are thioglycoside analogs of gangliosides represented by the formula ##STR1## in which Y represents a radical of the following formula ##STR2## and X represents a radical of the formula ##STR3## wherein m is an integer of 15 to 25, l is an integer of 0 to 3 and n is an integer of 11 to 15. The thioglycoside analogs are expected to exert specific enzyme-inhibitory effects.Type: GrantFiled: February 27, 1992Date of Patent: January 10, 1995Assignees: The Nisshin Oil Mills, Ltd., Akira HasegawaInventors: Akira Hasegawa, Makoto Kiso
-
Patent number: 5367062Abstract: Derivatives of disubstituted and deoxydisubstituted .alpha.-D-lyxofuranosides and intermediates for preparing these derivatives are described. These compounds exhibit significant antiinflammatory and anti-proliferative activity and are useful for treating inflammatory and/or autoimmune disorders such as psoriasis, asthma, atopic dermatitis, rheumatoid arthritis, osteoarthritis, scleroderma, systemic lupus erythematosus, and cancer (particularly melanoma and colon cancer).Type: GrantFiled: August 21, 1992Date of Patent: November 22, 1994Assignee: Medicarb Inc.Inventors: Sudershan K. Arora, Peter J. Schied
-
Patent number: 5349089Abstract: Cationic polysaccharide derivatives are prepared by reacting a polysaccharide with a polycationic reagent having one polysaccharide reactive group and at least two cationic groups. Suitable reagents include polycationic alkyl, aryl, alkaryl, cycloaliphatic, or heterocyclic amines, some of which are novel compositions. The polycationic polysaccharide derivatives prepared from these reagents are useful in the manufacture of paper.Type: GrantFiled: January 11, 1993Date of Patent: September 20, 1994Assignee: National Starch and Chemical Investment Holding CorporationInventors: Peter T. Trzasko, Michael T. Philbin
-
Patent number: 5340932Abstract: A process for the synthesis of a new N-acetylated Heparin derivative is disclosed which includes a reaction of a N-desulfated Heparin with acetic anhydride. The new compound so obtained and pharmaceutical compositions containing it, exhibit antithrombotic and fibrinolytic properties with low anticoagulant activity.Type: GrantFiled: September 16, 1992Date of Patent: August 23, 1994Assignee: Ajorca S.A.Inventors: Fernando Fussi, Victor Diaz, Ricardo H. Domanico, Esteban P. Fuentes
-
Patent number: 5319072Abstract: A method for purifying human antithrombin III in an alcoholic solution at low temperature using bound heparin is provided.Type: GrantFiled: January 10, 1992Date of Patent: June 7, 1994Assignee: Alpha Therapeutic CorporationInventors: Yahiro Uemura, Swaraj Kaur, Prabir Bhattcharya
-
Patent number: 5315002Abstract: Process for the preparation of a mercaptal of an oligosaccharide which process comprises the step of reacting the oligosaccharide with a thiol in the presence of an aqueous halocarboxylic or halosulphonic acid.Type: GrantFiled: January 25, 1993Date of Patent: May 24, 1994Assignee: Imperial Chemical Industries PLCInventors: Trevor Johnson, Robert A. C. Rennie
-
Patent number: 5298494Abstract: Derivatives of simple monosaccharides which exhibit anti-proliferative and/or anti-inflammatory activity and are useful for treating mammals having inflammatory disorders and/or autoimmune disorders. This invention also encompasses pharmaceutical compositions containing these compounds and methods of treating inflammatory and/or autoimmune disorders.Type: GrantFiled: June 30, 1993Date of Patent: March 29, 1994Assignee: Greenwich Pharmaceuticals IncorporatedInventors: Sudershan K. Arora, Roy L. Whistler, Albert V. Thomas
-
Patent number: 5280016Abstract: A non-anticoagulant (NAC) form of heparin which shows antiproliferative activity with respect to smooth muscle cells is useful in the prevention of restenosis and other conditions benefited by antiproliferative activity with respect to smooth muscle cells. This NAC form of heparin is prepared by oxidizing heparin/heparan sulfate to a desired level with periodate followed by reduction of the resulting aldehyde groups; all under conditions which prevent depolymerization of the heparin.Type: GrantFiled: September 3, 1991Date of Patent: January 18, 1994Assignee: Glycomed IncorporatedInventors: H. Edward Conrad, Yuchuan Guo
-
Patent number: 5273892Abstract: An acid heteropolysaccharide P-318 which comprises galactose, galacturonic acid, N-acetylfucosamine and pyruvic acid in a ratio of about 2:3:1:1, a sulfated heteropolysaccharide P-318 having a 10% or less sulfur content which is prepared by sulfating said acid heteropolysaccharide and a process for preparing an acid heteropolysaccharide P-318 which comprises culturing Pseudomonas sp. 318 to produce the acid heteropolysaccharide P-318 and collecting the thus produced acid heteropolysaccharide P-318. The sulfated polysaccharide P-318 of the invention shows a strong antiviral activity in spite of a lower content of sulfate.Type: GrantFiled: January 21, 1992Date of Patent: December 28, 1993Assignee: Teikoku Seiyaku Kabushiki KaishaInventor: Koichi Okutani
-
Patent number: 5268366Abstract: The present invention provides 1) a polysaccharide composition and a polysaccharide both having a heparinoid activity, obtained from green algae belonging to Codiaceae of Codiales, 2) a processes for producing said polysaccharide composition and said polysaccharide, as well as 3) an anticoagulant containing, as an active ingredient, said polysaccharide composition or polysaccharide both having a heparinoid activity.Type: GrantFiled: September 11, 1991Date of Patent: December 7, 1993Assignee: Nisshinbo Industries, Inc.Inventors: Masaakira Maeda, Tsutomu Uehara, Masao Takeshita
-
Patent number: 5264425Abstract: Salts of glycosaminoglycans (heparin, its fractions or fragments which are supersulfated, dermatan sulfate, heparan sulfate, and modified heparins) with bases of formula (I), ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, and R.sub.4 represent H, alkyl, or cycloalkyl; R.sub.5 and R.sub.6 represent H, or alkyl; R.sub.7 and R.sub.8 represent H or alkyl; n and m are integers from 1-4 and X is --O--CO--O--, which salts have the pharmacological properties of the glycosaminoglycans themselves, and are orally and rectally administrable.Type: GrantFiled: November 15, 1990Date of Patent: November 23, 1993Assignee: Italfarmaco S.p.A.Inventors: Alma Dal Pozzo, Maurizio Acquasaliente, Giancarlo Sportoletti, Monique Sarret, Paolo Ferruti, Francesco De Santis
-
Patent number: 5252728Abstract: The present invention consists in a process for obtaining polymers with antiviral activity which is characterized in that beginning with oligo or polysaccharides with a specific structure, polymers with a specific number of carbonyl groups are obtained by oxidation; in that the carbonyl groups of the oxidized oligo/polysaccharides are made to react with amino groups of molecules carrying amino and sulfonated groups, such as aliphatic aminosulfonates, in water or in mixtures of water with water-miscible solvents, under specific temperature, time, and pH conditions, giving rise to polymers carrying sulfonated groups, which are purified by conventional processes; in that the sulfonated polymers thus obtained have antiviral activity and either lack or present very low toxicity and anticoagulant activity, and are thus suitable for the production of pharmaceutical preparations suitable for use in topical or systemic antiviral therapy in humans or in animals. It is applicable in the pharmaceutical industry.Type: GrantFiled: December 13, 1991Date of Patent: October 12, 1993Assignee: Laboratorios Andromaco S.A.Inventors: Juan P. P. Ranieri, Antonio F. G. Gomez-Pamo, Luis C. Llamas, Jesus A. Armendariz, Juan A. Leal Ojeda, Carmen G. Benito
-
Patent number: 5242942Abstract: Compounds of the general formula (I): ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, n and p are as herein defined; exhibit anticonvulsant activity and are thus useful in the treatment of conditions such as epilepsy. Compounds of this class are also useful for the treatment of glaucoma, peptic ulcers, hypertension, congestive heart failure and other types of edema. Furthermore, pharmaceutical compositions containing a compound of formula (I) as well as methods for their use and novel intermediates are disclosed.Type: GrantFiled: April 28, 1992Date of Patent: September 7, 1993Assignee: McNeilab, Inc.Inventors: Michael J. Costanzo, Bruce E. Maryanoff
-
Patent number: 5234914Abstract: A method of treating hemorrhoids and anorectal disease which includes applying to the hemorrhoids and anorectal tissues an effective amount of a composition including a pharmaceutically acceptable carrier and hyaluronic acid or pharmaceutically acceptable salts thereof.Type: GrantFiled: November 27, 1991Date of Patent: August 10, 1993Assignee: Patent Biopharmaceutics, Inc.Inventor: Damian J. Gallina
-
Patent number: 5227479Abstract: The present invention relates to an efficient new route for the preparation of (+)-nojirimycin and (+)-1-deoxynojirimycin which involves the stereoselective reductive amination of 1,2-O-isopropylidene-5-oxo-.alpha.-D-glucuronolactone. The reductive amination uses particular oximes of the 5-oxo compound.Type: GrantFiled: November 14, 1990Date of Patent: July 13, 1993Assignee: Merrell Dow Pharmaceuticals Inc.Inventors: Peter B. Anzeveno, Laura J. Creemer
-
Patent number: 5227481Abstract: Cationic polysaccharide derivatives are prepared by reacting a polysaccharide with a polycationic reagent having one polysaccharide reactive group and at least two cationic groups. Suitable reagents include polycationic alkyl, aryl, alkaryl, cycloaliphatic, or heterocyclic amines, some of which are novel compositions. The polycationic polysaccharide derivatives prepared from these reagents are useful in the manufacture of paper.Type: GrantFiled: April 9, 1991Date of Patent: July 13, 1993Assignee: National Starch and Chemical Investment Holding CorporationInventors: John J. Tsai, Peter T. Trzasko, Michael T. Philbin, Robert L. Billmers, Martin M. Tessler, Joseph A. Van Gompel, Morton W. Rutenberg
-
Patent number: 5216145Abstract: Novel processes, intermediates and reagents for the preparation of 3-substituted furanose or furanoside compounds of Formula I: ##STR1## wherein M is hydrogen or alkyl (C.sub.1 -C.sub.3), A is halogen or A may be selected from a moiety of the formula: OR, SR, N.sub.3, SCR, OC-R or CN wherein R is hydrogen, branched or unbranched alkyl (C.sub.1 -C.sub.4) or phenyl which compounds have antiviral and other biological activity.Type: GrantFiled: May 10, 1991Date of Patent: June 1, 1993Assignee: American Cyanamid CompanyInventor: Yuri E. Raifeld
-
Patent number: 5164377Abstract: The present invention relates to sulphated glycosamino glycuronan with antithrombotic activity consisting essentially of salts of dermatan sulphate, chondroitin sulphate and heparan sulphate, characterized bya) an average molecular weight between 4000 and 8000 daltons;b) a nitrogen content between 2.4 and 3.0%;c) a sulphur content between 7.5 and 9.5%;d) a sodium content between 9 and 11%;e) a dermatan sulphate content between 5 and 25%;f) a chondroitin sulphate content less than 9%;g) an anti-Xa activity between 11 and 20 .mu./mg; andh) an antithrombin III dependent antithrombin activity of less than 1 .mu./mg.Type: GrantFiled: October 3, 1990Date of Patent: November 17, 1992Assignee: Akzo N.V.Inventors: Gijsbert W. K. Van Dedem, Francois E. A. Van Hou Denhoven, Dirk G. Meuleman, Huibert C. T. Moelker, Adrianus L. M. Sanders
-
Patent number: 5164378Abstract: A process for the depolymerization and supersulfation of heparin and the so obtained supersulfated heparins are disclosed. The process comprises treating heparin with oleum containing from 2 to 6% free sulfuric anhydride at a temperature from -10.degree. to +20.degree. C. The obtained heparins have molecular weights from 2000 to 5000 and a sulfation degree from 3.4 to 4.3. All of them are endowed with a remarkable antithrombotic activity.Type: GrantFiled: November 26, 1990Date of Patent: November 17, 1992Assignee: Iketon Farmaceutici, S.r.l.Inventors: Renato Conti, Paolo Casati, Maria B. Gorini, Antonio Maggi
-
Patent number: 5153181Abstract: The subject matter of the invention is the use of organic polymers which contain inorganic anionic groups for prophylaxis and therapy of retrovirus infections in mammals.Type: GrantFiled: January 16, 1987Date of Patent: October 6, 1992Assignees: Max-Planck-Gesellschaft zur Forderung der Wissenschaft E.V., The Federal Republic of Germany as represented by the Federal Minister of Youth and HealthInventors: Heino Diringer, Karin Molling
-
Patent number: 5145841Abstract: Method for the treatment of arthritis, rheumatism and inflammation of connective tissue in which a multivalent metal ion substantially pure complex of xylan polysulphate, wherein the multivalent metal ion is selected from the group consisting of Ca.sup.2+, Mg.sup.2+, Cu.sup.2+ and Zn.sup.2+ is administered to a patient in need of such treatment.Type: GrantFiled: September 19, 1989Date of Patent: September 8, 1992Assignee: Arthropharm PTY. LimitedInventors: David Cullis-Hill, Peter Ghosh
-
Patent number: 5138044Abstract: Reaction schemes for carrying out a variety of chemical synthesis are disclosed. The reactions produce .alpha.-(X)-sialosides wherein X is O, S, N or another compatible electron donating atom or molecular moiety. The reaction schemes include a relatively small number of steps to provide a yield with a relatively small amount of undesired .beta.-configuration product. Compounds synthesized are encompassed by the following general structural formula I. ##STR1## wherein R, R' and R" are each independently H, CH.sub.3, acetyl, or a disaccharide which is preferably lactose.Type: GrantFiled: August 13, 1990Date of Patent: August 11, 1992Assignee: Glycomed, Inc.Inventor: Falguni Dasgupta
-
Patent number: 5126347Abstract: Isomeric derivatives of 2',3'-dideoxyadenosine and 2',3'-dideoxyguanosine wherein the adenine or guanine base is attached to the 1' position of the iso-dideoxysugar residue by the 9-N position, the novel intermediates used in the synthesis of these compounds, and a method for treating a subject infected with a retrovirus by administering the compounds of the invention.Type: GrantFiled: February 13, 1989Date of Patent: June 30, 1992Assignee: Hoffmann-La Roche Inc.Inventors: Donna M. Huryn, Steve Yik-Kai Tam, Manfred Weigele
-
Patent number: 5116963Abstract: A process for preparing dermatan sulphate (DS) of pharmaceutical purity from animal organs rich in micropolysaccharides (MPS), by: a) stabilizing the fresh organs by freezing them either as such or in the form of powder, b) micronizing the material containing the MPS with an aqueous CaCl.sub.2 solution, c) digesting the homogenate comprising the raw material and the CaCl.sub.2 with proteolytic enzyme at alkaline pH and at low temperature, d) acidifying, heating and filtering the lysate, e) treating the filtrate with quaternary ammonium salts able to undergo complexing with and thus precipitate either the DS alone or all the MPS selectively, f) recovering and purifying the DS either directly from the ammonium salt complex containing it or from the complex obtained from the mixture of ammonium salt complexes of all the MPS by fractional solubilization with acetone.Type: GrantFiled: October 23, 1990Date of Patent: May 26, 1992Assignee: Mediolanum Farmaceutici SrlInventors: Rinaldo Del Bono, Luigi De Ambrosi, Gianni Ferrari, Pier L. Rugarli, Pier G. Pagella
-
Patent number: 5089606Abstract: A water-insoluble polysaccharide hydrogel foam and a method and article of preparing a homogeneously foamed hydrogel from a two component aqueous system of water-soluble polysaccharides bearing pendant carboxylate groups. The hydrogel foam, when it incorporates an antimicrobial, has particular utility as a surgical preparation for vaginal or rectal surgery.Type: GrantFiled: August 13, 1990Date of Patent: February 18, 1992Assignee: Minnesota Mining and Manufacturing CompanyInventors: Susan M. Cole, James E. Garbe, Lewis P. Woodson